Mylan brought a motion for directions seeking an elevated lump sum costs award following its successful counterclaim in a complex drug patent proceeding regarding the 684 Patent.
The Court found that an elevated lump sum award of 30% of actual reasonable legal fees was appropriate given the importance and complexity of the issues, awarding Mylan $878,218.00 inclusive of fees, disbursements, and tax, plus post-judgment interest.
